Post by LabConnect

Progress in sickle cell disease research is accelerating, creating new possibilities for more than 20 million people worldwide. Advances in scientific understanding and emerging therapies are bringing meaningful new treatment options closer to clinical reality. Turning that progress into patient impact requires precise coordination across complex global studies. LabConnect supports hematology, rare disease, and cell and gene therapy studies, along with other specialized, high-touch trials, by combining scientific and operational expertise with a curated global laboratory network, integrated logistics, and enabling technology to drive the full clinical trial sample journey. Every sample handled with care brings better treatment options closer to the patients who need them —  #WorldSickleCellDay2026 and every day. #OwnYourHealth #LabLikeNoOther #ClinicalResearch #ClinicalTrials #Biotech #Pharma Global Alliance of Sickle Cell Disease Organizations